pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
Eltanexor
Phase 1 · small molecule · Relapsed Myelodysplastic Syndrome
Eltanexor for Relapsed Myelodysplastic Syndrome is a Phase 1 program (small_molecule) at Karyopharm Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code VICC-VCHEM23008P
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Karyopharm Therapeutics Inc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Relapsed Myelodysplastic Syndrome
- Status
- active
- Trials
- 1